Please note: Work is currently underway to update content available on this site.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Publication #8689
Reference
MSAN(2026)14
Name
Levemir® (insulin detemir) FlexPen® 100units/ml solution for injection 3ml pre-filled pens and Levemir® (insulin detemir) Penfill 100units/ml solution for injection 3ml cartridges - Update Priority: Level 2*
Categories
Scottish Government
Drug Alerts
Organization
Scottish Government Health and Social Care Directorates
Keywords
NHS
Scotland
Health Board
Supplies
Pharmaceutical Services
Description
Levemir® (insulin detemir) FlexPen® 100units/ml solution for injection 3ml pre-filled pens and Levemir® (insulin detemir) Penfill® 100units/ml solution for injection 3ml cartridges are being discontinued; stock is anticipated to be exhausted by the end of 2026.
Clinical guidance has been produced by clinical experts (see Additional information section).
Current supply positions and ability of alternative insulins to support an increase in demand are summarised below. Any changes to availability will be communicated via the Medicines Supply Tool located on the Specialist Pharmacy Service website (registration required).
This MSAN recirculates the guidance from MSAN (2025) 41, issued on 25 August 2025. As a significant number of patients remain on Levemir® products, healthcare professionals are reminded to switch patients to a suitable alternative as soon as possible. Patients should be switched in line with the guidance attached.
Clinical guidance has been produced by clinical experts (see Additional information section).
Current supply positions and ability of alternative insulins to support an increase in demand are summarised below. Any changes to availability will be communicated via the Medicines Supply Tool located on the Specialist Pharmacy Service website (registration required).
This MSAN recirculates the guidance from MSAN (2025) 41, issued on 25 August 2025. As a significant number of patients remain on Levemir® products, healthcare professionals are reminded to switch patients to a suitable alternative as soon as possible. Patients should be switched in line with the guidance attached.
Contact Name
Contact Email
Contact Address
Created
2026-04-23 10:18:57
Click to go back to homepage